Recursion Pharmaceuticals IncNASDAQ:RXRX
- LAST PRICE7.3500
- TODAY'S CHANGE (%)0.1900 (2.6536%)
- Bid / Lots7.3400/ 7
- Ask / Lots7.3600/ 5
- Open / Previous Close7.2300 / 7.1600
- Day Range
- 52 Week Range
- Volume3,235,019
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RXRX |
|---|---|---|
| 09:32 ET | 113609 | 7.22 |
| 09:34 ET | 34738 | 7.19 |
| 09:36 ET | 19855 | 7.12 |
| 09:38 ET | 18969 | 7.15 |
| 09:39 ET | 26151 | 7.21 |
| 09:41 ET | 26490 | 7.23 |
| 09:43 ET | 9453 | 7.24 |
| 09:45 ET | 13560 | 7.21 |
| 09:48 ET | 21701 | 7.19 |
| 09:50 ET | 14815 | 7.2 |
| 09:52 ET | 19562 | 7.19 |
| 09:54 ET | 24224 | 7.2 |
| 09:56 ET | 18921 | 7.195 |
| 09:57 ET | 5863 | 7.17 |
| 09:59 ET | 7006 | 7.185 |
| 10:01 ET | 56627 | 7.285 |
| 10:03 ET | 19950 | 7.2549 |
| 10:06 ET | 19319 | 7.235 |
| 10:08 ET | 6698 | 7.285 |
| 10:10 ET | 18930 | 7.2972 |
| 10:12 ET | 25035 | 7.3021 |
| 10:14 ET | 25767 | 7.365 |
| 10:15 ET | 62286 | 7.42 |
| 10:17 ET | 52097 | 7.44 |
| 10:19 ET | 96129 | 7.485 |
| 10:21 ET | 60990 | 7.495 |
| 10:24 ET | 92456 | 7.515 |
| 10:26 ET | 30154 | 7.549 |
| 10:28 ET | 79205 | 7.5 |
| 10:30 ET | 24302 | 7.47 |
| 10:32 ET | 23071 | 7.51 |
| 10:33 ET | 29289 | 7.495 |
| 10:35 ET | 66585 | 7.465 |
| 10:37 ET | 23042 | 7.46 |
| 10:39 ET | 32269 | 7.43 |
| 10:42 ET | 24836 | 7.4393 |
| 10:44 ET | 41451 | 7.455 |
| 10:46 ET | 38537 | 7.43 |
| 10:48 ET | 27215 | 7.44 |
| 10:50 ET | 31134 | 7.45 |
| 10:51 ET | 21210 | 7.435 |
| 10:53 ET | 15117 | 7.42 |
| 10:55 ET | 20448 | 7.43 |
| 10:57 ET | 7851 | 7.41 |
| 11:00 ET | 15504 | 7.4 |
| 11:02 ET | 27605 | 7.445 |
| 11:04 ET | 13551 | 7.42 |
| 11:06 ET | 36137 | 7.42 |
| 11:08 ET | 11794 | 7.39 |
| 11:09 ET | 15516 | 7.39 |
| 11:11 ET | 16826 | 7.37 |
| 11:13 ET | 28843 | 7.39 |
| 11:15 ET | 9302 | 7.39 |
| 11:18 ET | 12499 | 7.375 |
| 11:20 ET | 23471 | 7.385 |
| 11:22 ET | 48151 | 7.3699 |
| 11:24 ET | 6588 | 7.37 |
| 11:26 ET | 32049 | 7.345 |
| 11:27 ET | 7850 | 7.35 |
| 11:29 ET | 8468 | 7.34 |
| 11:31 ET | 7112 | 7.345 |
| 11:33 ET | 9882 | 7.335 |
| 11:36 ET | 9951 | 7.33 |
| 11:38 ET | 5735 | 7.33 |
| 11:40 ET | 22745 | 7.3101 |
| 11:42 ET | 6568 | 7.31 |
| 11:44 ET | 10415 | 7.315 |
| 11:45 ET | 14503 | 7.33 |
| 11:47 ET | 10728 | 7.33 |
| 11:49 ET | 9063 | 7.335 |
| 11:51 ET | 14810 | 7.335 |
| 11:54 ET | 11547 | 7.32 |
| 11:56 ET | 7122 | 7.325 |
| 11:58 ET | 29848 | 7.325 |
| 12:00 ET | 16085 | 7.35 |
| 12:02 ET | 18934 | 7.3415 |
| 12:03 ET | 17391 | 7.37 |
| 12:05 ET | 10088 | 7.375 |
| 12:07 ET | 13868 | 7.3899 |
| 12:09 ET | 16254 | 7.38 |
| 12:12 ET | 13536 | 7.375 |
| 12:14 ET | 7276 | 7.365 |
| 12:16 ET | 9154 | 7.365 |
| 12:18 ET | 9249 | 7.34 |
| 12:20 ET | 10728 | 7.33 |
| 12:21 ET | 7148 | 7.345 |
| 12:23 ET | 15817 | 7.345 |
| 12:25 ET | 21994 | 7.355 |
| 12:27 ET | 11954 | 7.355 |
| 12:30 ET | 26876 | 7.375 |
| 12:32 ET | 8308 | 7.36 |
| 12:34 ET | 10412 | 7.365 |
| 12:36 ET | 12673 | 7.36 |
| 12:38 ET | 28796 | 7.395 |
| 12:39 ET | 20949 | 7.38 |
| 12:41 ET | 22771 | 7.375 |
| 12:43 ET | 20855 | 7.35 |
| 12:45 ET | 11117 | 7.335 |
| 12:48 ET | 20363 | 7.335 |
| 12:50 ET | 18754 | 7.345 |
| 12:52 ET | 18747 | 7.345 |
| 12:54 ET | 74621 | 7.35 |
| 12:56 ET | 31875 | 7.335 |
| 12:57 ET | 26372 | 7.335 |
| 12:59 ET | 98062 | 7.35 |
Jun 27, 2024
DJ Recursion Pharmaceuticals Shares Drop 19% After Public Offering Prices, from 12:47PM ET on Thursday Jun 27, 2024 by Dow Jones
12:47PM ET on Thursday Jun 27, 2024 by Dow JonesDJ Recursion Pharmaceuticals Down Nearly 18%, on Pace for Largest Percent Decrease Since March 2022 -- Data Talk, from 11:21AM ET on Thursday Jun 27, 2024 by Dow Jones
11:21AM ET on Thursday Jun 27, 2024 by Dow Jones
Jun 26, 2024
*DJ Recursion Pharmaceuticals Prices $200M Public Offering of Class A Common Stock >RXRX, from 10:17PM ET on Wednesday Jun 26, 2024 by Dow Jones
10:17PM ET on Wednesday Jun 26, 2024 by Dow JonesRecursion Announces Pricing of $200 Million Public Offering of Class A Common Stock, from 10:07PM ET on Wednesday Jun 26, 2024 by Dow Jones
10:07PM ET on Wednesday Jun 26, 2024 by Dow JonesDJ Recursion Pharmaceuticals Down 7.9% on Planned Secondary Offering, from 5:16PM ET on Wednesday Jun 26, 2024 by Dow Jones
5:16PM ET on Wednesday Jun 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Recursion Pharmaceuticals Inc | 2.0B | -4.5x | --- |
Protagonist Therapeutics Inc | 2.0B | 14.0x | --- |
Janux Therapeutics Inc | 2.0B | -31.4x | --- |
Intellia Therapeutics Inc | 2.2B | -4.3x | --- |
CG Oncology Inc | 2.1B | -27.4x | --- |
Iovance Biotherapeutics Inc | 2.1B | -4.1x | --- |
Company Information
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Contact Information
- Headquarters
- 41S Rio Grande StreetSALT LAKE CITY, UT, United States 84101
- Phone
- 385-269-0203
- Fax
- 801-581-7895
Executives
- Independent Chairman of the Board
- Robert Hershberg
- President, Chief Operating Officer
- Tina Larson
- Chief Executive Officer, Director
- Christopher Gibson
- Chief Financial Officer
- Michael Secora
- Director, Chief Research and Development Officer, Chief Commercial Officer
- Najat Khan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
|---|---|
Revenue (TTM) | $46.2M |
Shares Outstanding | 272.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.62 |
Book Value | $1.98 |
P/E Ratio | -4.5x |
Price/Sales (TTM) | 43.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -814.39% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
